Medication improves health of patients with pulmonary arterial hypertension

Nov 17, 2009

In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology.

A research team led by Ronald Oudiz, MD, FACC, a principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), conducted a follow-up of the studies conducted for the Food and Drug Administration's approval of ambrisentan. The researchers found 383 PAH patients treated for two years with ambrisentan had sustained improvements in their . The team also found a low risk of death and clinical worsening from the disease among the PAH patients treated with ambrisentan for two years.

"These are promising findings for patients who suffer from , an often fatal disease of the pulmonary circulation," said Dr. Oudiz. "Physicians and patients with PAH should consider the use of ambrisentan as part of a long-term strategy for treatment of the disease."

PAH is a disease of the pulmonary circulation often afflicting younger women and is characterized by a progressive elevation in pulmonary vascular resistance that leads to right ventricular failure and . Although the number of approved therapies for PAH has grown in the past 10 years, the disease remains rapidly progressive with a poor prognosis for most patients. Despite treatment, 25% to 50% of all patients with PAH will not survive beyond five years.

Ambrisentan is an orally active, once-daily medication currently approved for the treatment of PAH patients in the U.S. and other countries on the basis of two 12-week randomized, double-blind, placebo-controlled, multicenter efficacy trials. In these studies, the drug improved exercise capacity, along with other clinical indications of PAH disease severity, including clinical worsening.

Prior to their study, the researchers said most long-term PAH studies have focused primarily on exercise capacity and safety for up to one year, with very little description of clinical effectiveness of ambrisentan .

The researchers in the current two-year study found that the two higher doses of the medication, 5 milligrams and 10 milligrams, provided a sustained benefit. The lower dosage used in the study, 2.5 milligrams, was less effective, the researchers said.

Source: UCLA Medical Center

Explore further: Malaysia quarantines 64 villagers over MERS virus

add to favorites email to friend print save as pdf

Related Stories

A type of antioxidant may not be as safe as once thought

Sep 04, 2007

Certain preparations taken to enhance athletic performance or stave off disease contain an anti-oxidant that could cause harm. According to new research at the University of Virginia Health System, N-acetylcysteine (NAC), ...

Mars Rover device gets new mission on Earth

Feb 05, 2009

Developed to sniff out extraterrestrial life on other planets, a portable device known as the Mars Organic Analyzer (MOA) is taking on a new role in detecting air pollutants on Earth. Researchers in California ...

Endothelin drugs benefit those with pulmonary hypertension

Sep 10, 2009

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating ...

Recommended for you

Malaysia quarantines 64 villagers over MERS virus

38 minutes ago

Malaysia has quarantined 64 people in a southern village after one of its residents become the country's first person to die of a respiratory illness that is spreading from the Middle East, local media reported Thursday.

Spate of Mideast virus infections raises concerns

1 hour ago

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

New MRSA superbug emerges in Brazil

1 hour ago

An international research team led by Cesar A. Arias, M.D., Ph.D., at The University of Texas Health Science Center at Houston (UTHealth) has identified a new superbug that caused a bloodstream infection ...

User comments : 0

More news stories

Turning off depression in the brain

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Spate of Mideast virus infections raises concerns

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

Clean air: Fewer sources for self-cleaning

Up to now, HONO, also known as nitrous acid, was considered one of the most important sources of hydroxyl radicals (OH), which are regarded as the detergent of the atmosphere, allowing the air to clean itself. ...

Thinnest feasible nano-membrane produced

A new nano-membrane made out of the 'super material' graphene is extremely light and breathable. Not only can this open the door to a new generation of functional waterproof clothing, but also to ultra-rapid filtration. The ...

There's something ancient in the icebox

Glaciers are commonly thought to work like a belt sander. As they move over the land they scrape off everything—vegetation, soil, and even the top layer of bedrock. So scientists were greatly surprised ...